Britain's competition watchdog probes Iberdrola merger with NWEN-February 2024-www.financetom.com

Britain's competition watchdog probes Iberdrola merger with NWEN

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Britain's competition watchdog probes Iberdrola merger with NWEN

Jan 28, 2025 11:48 PM

LONDON, Jan 29 (Reuters) - Britain's Competition and

Markets Authority said on Wednesday it was weighing whether a

merger of Spain's Iberdrola and NWEN Ltd could reduce

competition in the energy sector, and make it tougher for market

regulators to keep track of pricing.

The CMA has set a deadline of March 27 for submissions by

interested parties to phase 1 of its merger enquiry.

Previous page： --ASML CEO Expects US Pressure for More China Chip Restrictions, Bloomberg Reports Next page： Quest Diagnostics CEO Touts 'New Customer Wins' In Q3, Expects Earnings Growth In 2025

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--ASML CEO Expects US Pressure for More China Chip Restrictions, Bloomberg Reports

Oct 22, 2024

11:17 AM EDT, 10/22/2024 (MT Newswires) -- Price: 720.42, Change: +6.32, Percent Change: +0.89 ...

Quest Diagnostics CEO Touts 'New Customer Wins' In Q3, Expects Earnings Growth In 2025

Oct 22, 2024

Quest Diagnostics Inc posted third-quarter adjusted earnings per share of $2.30, beating the consensus of $2.26. Sales increased 8.5% year-over-year to $2.49 billion, beating the consensus of $2.42 billion. Quest Diagnostics ( DGX ) saw total revenue growth of 8.5%, including 4.2% organic growth, said Quest Diagnostics CEO Jim Davis. “Our performance was driven by new customer wins and expanded business with physicians...

BriaCell Higher as it Reports "Standard-Beating" Survival Data From Phase 2 Study

Oct 22, 2024

11:06 AM EDT, 10/22/2024 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) was last seen up 3.6% after the company on Tuesday released new positive data in its Phase 2 metastatic breast cancer (MBC) study. In the study, patients treated with the same Bria-IMT regimen formulation being used in the ongoing Phase 3 pivotal trial experienced a one-year survival rate...

Sangamo Therapeutics Shares Surge After US FDA Clears Potential Fabry Disease Treatment for Expedited Review

Oct 22, 2024

11:10 AM EDT, 10/22/2024 (MT Newswires) -- Sangamo Therapeutics ( SGMO ) shares surged past 31% in recent Tuesday trading after the genomic medicine company said the US Food and Drug Administration has laid out a clear pathway for accelerated approval for its ST-920 gene therapy candidate for the treatment of Fabry disease. Fabry disease is a genetic condition characterized...